# Corvus Pharmaceuticals

Corvus Pharmaceuticals is an Asset Manager based in Burlingame, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Burlingame, United States
- **Region:** North America
- **Address:** Burlingame, CA, United States
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** corvuspharma.com

## Regulatory record

- **Reports private funds:** No

## About

Corvus Pharmaceuticals was established in 2014 by Richard A. Miller and Joseph J. Buggy, building on decades of prior drug-development experience to target immune-related mechanisms in cancer. The company's initial public offering on the NASDAQ followed in 2016, providing the capital base to advance its pipeline of small-molecule and monoclonal antibody therapies. Corvus structured its operations around wholly owned clinical programs rather than a portfolio-of-passive-investments model, with decision-making concentrated in its South San Francisco headquarters. The firm's deployment strategy revolves around running multiple Phase 1 and 1b clinical trials in parallel, primarily in solid tumors and hematologic malignancies. Core programs include the adenosine A2A receptor antagonist mupadolimab (formerly CPI-006), an IL-2 and IL-15 receptor beta/gamma agonist soquelitinib (formerly CPI-818), and the ITK inhibitor CPI-444. Corvus generates its own clinical data at sites across the United States, Canada, and Australia, with a pharmacological focus on reversing immune suppression in the tumor microenvironment. Partnerships have historically included a 2015 collaboration with Genentech on atezolizumab combination trials (per the firm's press releases). The management team includes Miller, whose prior venture was the oncology-focused Pharmacyclics (acquired by AbbVie for $21 billion in 2015), and Buggy, an enzymologist and biochemist by training. The leadership's track record, combined with an internal discovery engine, has defined the firm's operational posture more than headcount scale or disclosed assets under management. Structurally, Corvus operates as an internally funded, publicly traded biotech platform, not a venture-capital firm or a syndicated family-office vehicle. Its operating structure — where the CEO also functions as the chief scientific-strategy officer — centralizes resource allocation decisions around biomarker-driven clinical milestones, distinguishing it from diversified asset-gathering life-science platforms that spread risk across dozens of portfolio companies.

## Sectors

- Digital Health
- Healthcare Services

## People

- Richard A. Miller — Co-founder, President and CEO
- Joseph J. Buggy — Co-founder and Executive Vice President of Discovery Research

## Questions

### What is Corvus Pharmaceuticals' lead clinical program?

The lead program is soquelitinib (formerly CPI-818), an oral interleukin-2 receptor beta and gamma agonist designed to selectively inhibit T-cell lymphomas while sparing regulatory T-cells. Corvus reported updated Phase 1/1b results for the molecule in March 2024 that showed encouraging response rates in relapsed peripheral T-cell lymphoma (per the firm's corporate presentation, 2024). The company has initiated a registrational Phase 3 trial based on these data.

### Who runs day-to-day R&D decisions at Corvus?

Richard A. Miller, the co-founder, President and CEO, drives the strategic research direction alongside co-founder Joseph J. Buggy, who oversees discovery research and early development. Miller's previous venture, Pharmacyclics, developed the blockbuster BTK inhibitor ibrutinib prior to an acquisition by AbbVie, giving the leadership bench deep hands-on experience in oncology translational science.

### Does Corvus partner externally with large pharma companies?

Historically yes. In 2015, the firm entered a combination-trial collaboration with Genentech (Roche) to evaluate Corvus's adenosine A2A receptor antagonist alongside the PD-L1 inhibitor atezolizumab in solid tumors. More recent pipeline progress has emphasized wholly owned programs with an internal clinical-operations footprint rather than a partner-dependent model.

### What differentiates Corvus from other early-stage oncology developers?

The firm integrates biomarker analysis at every stage of early clinical trials, selecting patient populations based on adenosine or ITK pathway signatures rather than tumor type alone. This immunologic stratification approach is designed to surface efficacy signals faster than conventional histology-dependent Phase 1 designs.

## Related profiles

- [Phoenix Education Partners](https://altss.com/profile/phoenix-education-partners-inc)
- [Tamboran Resources Corp](https://altss.com/profile/tamboran-resources-corp)

---

Last updated: 2026-08-11T02:43:31.692Z

Canonical page: https://altss.com/profile/corvus-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology